XML 23 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Financial Data
3 Months Ended
Mar. 31, 2023
Supplemental Financial Data [Abstract]  
Supplemental Financial Data [Text Block]
3. Supplemental Financial Data


Inventories


Our inventory consisted of the following (in thousands):

 
March 31, 2023
   
December 31, 2022
 
Raw materials:
           
Raw materials - clinical
 
$
17,356
   
$
17,061
 
Raw materials - commercial
   
2,786
     
2,699
 
Total raw materials
   
20,142
     
19,760
 
Work in process
   
1,840
     
2,109
 
Finished goods
   
218
     
164
 
Total inventory
 
$
22,200
   
$
22,033
 


Accrued Liabilities


Our accrued liabilities consisted of the following (in thousands):

 
March 31, 2023
   
December 31, 2022
 
Clinical development expenses
 
$
85,694
   
$
116,460
 
In-licensing expenses
   
12,704
     
7,945
 
Commercial expenses
   
4,704
     
3,498
 
Other miscellaneous expenses
   
9,600
     
12,198
 
Total accrued liabilities
 
$
112,702
   
$
140,101